Certain types of life science research involving “high consequence pathogens and toxins” would be subject to new review and risk mitigation procedures which might include classification of the research or termination of the funding, according to a U.S. government policy issued yesterday by the National Institutes of Health.
The policy applies to research involving 15 specified biological agents and toxins which “pose the greatest risks of deliberate misuse with most significant potential for mass casualties or devastating effects to the economy, critical infrastructure or public confidence.”
Research that increases the lethality or transmissibility of the agent or toxin, or otherwise enhances its harmful consequences, will be subject to the new review procedures.
Based on the outcome of the review, a risk mitigation plan may be developed. If less restrictive measures were deemed inadequate, the new policy would allow for national security classification of the research or termination of government funding.
See “United States Government Policy for Oversight of Life Sciences Dual Use Research of Concern,” March 29, 2012.
See also “U.S. Requires New Dual-Use Biological Research Reviews” by David Malakoff, Science Insider, March 29.
Coordination among federal science agencies is essential to ensure government-wide alignment on R&D investment priorities. However, the federal R&D enterprise suffers from egregious siloization.
Don’t like the Chinese-backed EVs that are undercutting your market? Start with a well-designed statute to strengthen market oversight and competition while also providing American companies with support.
Cities and states are best positioned to design policies to accelerate clean energy, innovation, and economic development because they can design approaches that work in different social, political, and economic contexts.
Outcome-Based Contracting reframes procurement around the staged achievement of measurable mission outcomes rather than the delivery of predefined technical artifacts.